4 completed, 2 active not recruiting, 2 unknown, 1 recruiting. 4 Phase 2, 2 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Unknown 1 |
| Not applicable | 2 | Active not recruiting 1, Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Carcinoma Breast: new trials by email Literature Review of Carcinoma Breast trials Research Report on Carcinoma Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Dosimetric Comparison of Target Volume, Heart and Left Lung in Post Mastectomy Radiotherapy (RT) of Left Sided Breast Cancer by Free Breathing (FB) Versus Deep Inspiration Breath Hold (DIBH) Technique Deep inspiration breath hold radiotherapy, Free breathing radiotherapy - Carcinoma Breast, Radiation Therapy for Primary Breast Cancer | Not applicable | Active not recruiting | Nishat Tasnim | 50 | 2024-07-17 | 2024-12-24 |
| Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor - Carcinoma, Non-Small-Cell Lung, Carcinoma Breast | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 45 | 2022-10-30 | 2022-11-02 |
| Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment. Biomarkers - Neoplasm, Breast, Carcinoma Breast | Unknown | Universiteit Antwerpen | 150 | 2022-10-04 | 2023-12-27 | |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Pleural Effusion, Malignant, Ascites, Malignant | Completed | Travera Inc | 72 | 2022-07-15 | 2026-04-13 | |
| Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer Huaier Granule - Carcinoma Breast, Triple-negative Breast Cancer | Phase 4 | Recruiting | Fudan University | 1072 | 2021-06-18 | 2024-06-27 |
| Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy Caffeine anhydrous 5% added to Lipoderm Cream Base., Lipoderm Cream Base - Carcinoma Breast | Phase 2 | Active not recruiting | NYU Langone Health | 60 | 2020-06-29 | 2026-06-04 |
| Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Investigational Imaging device, AVB-620 - Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast | Phase 2 | Completed | Avelas Biosciences, Inc. | 92 | 2017-07-05 | 2021-06-11 |
| Randomized Trial on Intraoperative Radiotherapy Full Dose Vs External Radiotherapy external fractionated radiotherapy, intraoperative radiotherapy - Carcinoma Breast | Not applicable | Completed | European Institute of Oncology | 1305 | 2000-11-01 | 2013-05-08 |
| Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Breast conservative surgery - Carcinoma Breast | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 224 | 2000-03-01 | 2016-12-26 |
Breast Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (3) · Anus Neoplasms (2) · Appendiceal Neoplasms (2) · Carcinoma (2) · Carcinoma, Ductal, Breast (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Neuroendocrine (2) · Carcinoma, Renal Cell (2) · Cholangiocarcinoma (2) · Esophageal Neoplasms (2) · Laryngeal Neoplasms (2) · Lung Neoplasms (2) · Mesothelioma (2) · Mouth Neoplasms (2)
Breast Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Adenocarcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Ductal, Lobular, and Medullary (4) · Neoplasms, Glandular and Epithelial (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Carcinoma, Ductal (3) · Lung Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Respiratory Tract Diseases (3)
Drugs, Investigational (1) · Environmental Biomarkers (1) · Gene Expression (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Immune Checkpoint Inhibitors (1) · Interleukin-2 (1) · Polymorphism, Single Nucleotide (1) · Radiotherapy (1) · Vinorelbine (1)
Travera Inc (2) · Avelas Biosciences, Inc. (1) · European Institute of Oncology (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fudan University (1) · NYU Langone Health (1) · Nishat Tasnim (1) · Second Affiliated Hospital of Soochow University (1) · Universiteit Antwerpen (1)
United States (3) · China (2) · Italy (2) · Bangladesh (1) · Belgium (1)
An De Groef, Prof. (1) · Mark Stevens, Ph.D. (1) · Mark Stevens, Phd (1) · Massimiliano Gennaro, MD (1) · Mira Meeus, Prof. (1) · Most. Rokaya Sultana, MBBS, MD (1) · Naamit Kurshan Gerber (1) · Rob Kimmerling, Phd (1) · Robert Kimmerling, Ph.D. (1) · Steven Chen, MD, MBA (1) · Zhimin Shao, PhD (1)
PMID 10376613, PMID 10430251, PMID 10547549, PMID 11267852, PMID 14596511, PMID 14965620, PMID 16801628, PMID 16864033, PMID 16934611, PMID 16978941, PMID 18250350, PMID 18473330, PMID 19635166, PMID 19636625, PMID 20956824, PMID 21145284, PMID 24043739, PMID 24163223, PMID 24225155, PMID 25600630, PMID 25798382, PMID 26686313, PMID 26686957, PMID 26834064, PMID 27396337, PMID 27733270, PMID 33845035, PMID 5910392, PMID 8635094, PMID 9469327